$MTEM
Molecular Templates, Inc.

2022 Q3 Form 10-Q Financial Statement

#000156459022029202 Filed on August 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $4.240M $4.417M $8.486M
YoY Change 78.23% -70.81% 163.54%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.934M $6.566M $7.620M
YoY Change -34.26% -26.41% -6.85%
% of Gross Profit
Research & Development $21.97M $21.37M $21.50M
YoY Change -3.97% 1.13% 0.6%
% of Gross Profit
Depreciation & Amortization $2.000M $1.900M $1.872M
YoY Change 17.65% 18.75% 24.06%
% of Gross Profit
Operating Expenses $27.91M $27.93M $29.12M
YoY Change -12.54% -7.05% -1.46%
Operating Profit -$23.67M -$23.51M -$20.63M
YoY Change -19.85% 57.65% -21.64%
Interest Expense $307.0K $186.0K $70.00K
YoY Change 75.43% 129.63% 34.62%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$24.61M -$24.42M -$21.61M
YoY Change -19.0% 56.53% -19.3%
Income Tax $26.00K
% Of Pretax Income
Net Earnings -$24.64M -$24.42M -$21.61M
YoY Change -18.92% 56.53% -19.3%
Net Earnings / Revenue -581.08% -552.86% -254.67%
Basic Earnings Per Share -$0.44 -$0.43 $0.38
Diluted Earnings Per Share -$0.44 -$0.43 -$383.8K
COMMON SHARES
Basic Shares Outstanding 56.35M 56.33M 56.31M
Diluted Shares Outstanding 56.35M 56.33M 56.31M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $79.45M $104.4M $124.5M
YoY Change -53.1% -47.15% -38.45%
Cash & Equivalents $22.28M $26.94M $19.57M
Short-Term Investments $57.17M $77.49M $104.9M
Other Short-Term Assets $4.011M $4.358M $7.866M
YoY Change -50.29% -43.23% 994.02%
Inventory
Prepaid Expenses $3.729M $2.395M
Receivables
Other Receivables
Total Short-Term Assets $87.19M $111.2M $132.4M
YoY Change -50.87% -45.84% -36.71%
LONG-TERM ASSETS
Property, Plant & Equipment $16.35M $17.91M $18.63M
YoY Change -20.07% -15.53% -14.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Other Assets $3.994M $4.006M $3.940M
YoY Change -20.42% -20.92% -23.44%
Total Long-Term Assets $31.46M $29.71M $30.78M
YoY Change -22.29% -24.74% -27.73%
TOTAL ASSETS
Total Short-Term Assets $87.19M $111.2M $132.4M
Total Long-Term Assets $31.46M $29.71M $30.78M
Total Assets $118.6M $140.9M $163.2M
YoY Change -45.56% -42.44% -35.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.085M $1.641M $0.00
YoY Change -17.24% -13.95% -100.0%
Accrued Expenses $8.890M $9.291M $7.905M
YoY Change -21.36% 2.39% -19.34%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $50.22M $46.38M $45.02M
YoY Change 5.96% 3.73% -41.2%
LONG-TERM LIABILITIES
Long-Term Debt $35.94M $35.68M $35.74M
YoY Change 1.95% 1.88% 137.76%
Other Long-Term Liabilities $1.269M $1.698M $34.92M
YoY Change -97.99% -97.49% 2192.97%
Total Long-Term Liabilities $37.21M $37.37M $70.66M
YoY Change -62.2% -63.59% 326.84%
TOTAL LIABILITIES
Total Short-Term Liabilities $50.22M $46.38M $45.02M
Total Long-Term Liabilities $37.21M $37.37M $70.66M
Total Liabilities $114.5M $114.9M $115.7M
YoY Change -21.48% -22.06% -19.34%
SHAREHOLDERS EQUITY
Retained Earnings -$422.7M -$398.1M
YoY Change
Common Stock $427.1M $424.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.152M $26.04M $47.48M
YoY Change
Total Liabilities & Shareholders Equity $118.6M $140.9M $163.2M
YoY Change -45.56% -42.44% -35.19%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$24.64M -$24.42M -$21.61M
YoY Change -18.92% 56.53% -19.3%
Depreciation, Depletion And Amortization $2.000M $1.900M $1.872M
YoY Change 17.65% 18.75% 24.06%
Cash From Operating Activities -$24.43M -$18.47M -$27.70M
YoY Change -1.54% -27.07% -165.61%
INVESTING ACTIVITIES
Capital Expenditures -$986.0K -$1.347M $553.0K
YoY Change -25.47% -0.22% 27.13%
Acquisitions
YoY Change
Other Investing Activities $20.57M $27.45M $21.84M
YoY Change 110.29% -156.06% -154.66%
Cash From Investing Activities $19.58M $26.11M $21.29M
YoY Change 131.52% -151.88% -152.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.000K -274.0K 0.000
YoY Change -98.95% -101.37% -100.0%
NET CHANGE
Cash From Operating Activities -24.43M -18.47M -27.70M
Cash From Investing Activities 19.58M 26.11M 21.29M
Cash From Financing Activities 9.000K -274.0K 0.000
Net Change In Cash -4.838M 7.364M -6.411M
YoY Change -68.78% -113.22% -108.71%
FREE CASH FLOW
Cash From Operating Activities -$24.43M -$18.47M -$27.70M
Capital Expenditures -$986.0K -$1.347M $553.0K
Free Cash Flow -$23.44M -$17.12M -$28.25M
YoY Change -0.2% -28.59% -167.62%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14915000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42379000
us-gaap Operating Income Loss
OperatingIncomeLoss
-41244000
CY2021Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
81000
us-gaap Net Income Loss
NetIncomeLoss
-46031000
us-gaap Net Income Loss
NetIncomeLoss
-42379000
us-gaap Operating Expenses
OperatingExpenses
57048000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
133000
mtem Interest And Other Expense Net
InterestAndOtherExpenseNet
2142000
mtem Interest And Other Expense Net
InterestAndOtherExpenseNet
1268000
us-gaap Share Based Compensation
ShareBasedCompensation
6664000
us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
73000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
264000
us-gaap Interest Paid Net
InterestPaidNet
725000
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents Asset Statement Of Financial Position Extensible List
RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherAssets
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents Asset Statement Of Financial Position Extensible List
RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherAssets
CY2022Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M3D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M19D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M23D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y5M23D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y3M10D
CY2022Q2 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
4417000
CY2021Q2 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
15134000
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
12903000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21365000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42447000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8922000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14186000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17151000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
27931000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
30049000
us-gaap Operating Expenses
OperatingExpenses
59598000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-23514000
us-gaap Operating Income Loss
OperatingIncomeLoss
-44145000
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
186000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
256000
CY2022Q2 mtem Interest And Other Expense Net
InterestAndOtherExpenseNet
1092000
CY2021Q2 mtem Interest And Other Expense Net
InterestAndOtherExpenseNet
767000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-24420000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-15601000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24420000
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.82
mtem Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
-453000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.82
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.78
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.78
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56329585
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56329585
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56096238
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56096238
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56317384
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54340173
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54340173
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56317384
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-42000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1522000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1132000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
0
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-234000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
892000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-763000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24420000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15601000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-46031000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42379000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-31000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-282000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-9000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24451000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15595000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46313000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42388000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
47482000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
108355000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
65662000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
59340000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
26037000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
97402000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
97402000
us-gaap Share Based Compensation
ShareBasedCompensation
8579000
mtem Interest Accrued On Long Term Debt
InterestAccruedOnLongTermDebt
-24000
mtem Interest Accrued On Long Term Debt
InterestAccruedOnLongTermDebt
137000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
482000
us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
66000
mtem Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
-46000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-247000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-498000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-367000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3902000
mtem Increase Decrease In Other Noncurrent Liabilities Related Parties
IncreaseDecreaseInOtherNoncurrentLiabilitiesRelatedParties
0
mtem Increase Decrease In Other Noncurrent Liabilities Related Parties
IncreaseDecreaseInOtherNoncurrentLiabilitiesRelatedParties
-11853000
mtem Increase Decreases In Collaboration Revenue
IncreaseDecreasesInCollaborationRevenue
-10641000
mtem Increase Decreases In Collaboration Revenue
IncreaseDecreasesInCollaborationRevenue
64783000
mtem Increase Decrease In Deferred Revenue Related Parties Current
IncreaseDecreaseInDeferredRevenueRelatedPartiesCurrent
0
mtem Increase Decrease In Deferred Revenue Related Parties Current
IncreaseDecreaseInDeferredRevenueRelatedPartiesCurrent
-1309000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46165000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
16884000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1900000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1790000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
39097000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
144620000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
88389000
mtem Research And Development Revenues From Collaboration Agreements
ResearchAndDevelopmentRevenuesFromCollaborationAgreements
18354000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
55700000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
47392000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-90710000
mtem Payments Of Capital And Financing Lease Obligations
PaymentsOfCapitalAndFinancingLeaseObligations
0
mtem Payments Of Capital And Financing Lease Obligations
PaymentsOfCapitalAndFinancingLeaseObligations
1000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
19828000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
24000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
726000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
71145000
mtem Fees Paid On Loan Modification
FeesPaidOnLoanModification
298000
mtem Fees Paid On Loan Modification
FeesPaidOnLoanModification
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-274000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
91698000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
953000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
17872000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28651000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28886000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
29604000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
46758000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26936000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43090000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
2668000
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3668000
us-gaap Interest Paid Net
InterestPaidNet
1556000
mtem Fixed Asset Additions In Accounts Payable And Accrued Expenses
FixedAssetAdditionsInAccountsPayableAndAccruedExpenses
443000
mtem Fixed Asset Additions In Accounts Payable And Accrued Expenses
FixedAssetAdditionsInAccountsPayableAndAccruedExpenses
319000
CY2022Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
104400000
CY2022Q2 us-gaap Depreciation
Depreciation
1900000
CY2021Q2 us-gaap Depreciation
Depreciation
1600000
us-gaap Depreciation
Depreciation
3700000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash and cash equivalents, investments, long term debt and accounts receivable.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s cash and cash equivalents are with two major financial institutions in the United States.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company performs an ongoing credit evaluation of its strategic partners’ financial conditions and generally does not require collateral to secure accounts receivable from its strategic partners. The Company’s exposure to credit risk associated with non-payment will be affected principally by conditions or occurrences within Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd. (“Takeda”), <span style="Background-color:#FFFFFF;color:#000000;">Vertex Pharmaceuticals Incorporated (“Vertex”) and Bristol Myers Squibb Company (“Bristol Myers Squibb”)</span>. Takeda accounted for approximately 0% and 85% of total revenues for the three months ended June 30, 2022 and 2021, respectively and approximately 20% and 72% of total revenues for the six months ended June 30, 2022 and 2021. Vertex accounted for approximately 0% and 2% of total revenues for the three months ended June 30, 2022 and 2021, respectively and 0% and 13% of total revenues for the six months ended June 30, 2022 and 2021. <span style="Background-color:#FFFFFF;color:#000000;">Bristol Myers Squibb</span> accounted for approximately 100% and 13% of total revenues for the three months ended June 30, 2022 and 2021, respectively and approximately 80% and 16% of total revenues for the six months ended June 30, 2022 and 2021.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug or biologic candidates developed by the Company may require approvals or clearances from the U.S. Food and Drug Administration (“FDA”) or international regulatory agencies prior to commercial sales. There can be no assurance that the Company’s drug or biologic candidates will receive any of the required approvals or clearances. If the Company were to be denied approval or clearance or any such approval or clearance were to be delayed, it would have a material adverse impact on the Company.</p>
CY2022Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
102972000
CY2022Q2 mtem Research And Development Revenues From Collaboration Agreements
ResearchAndDevelopmentRevenuesFromCollaborationAgreements
4417000
CY2021Q2 mtem Research And Development Revenues From Collaboration Agreements
ResearchAndDevelopmentRevenuesFromCollaborationAgreements
15134000
mtem Research And Development Revenues From Collaboration Agreements
ResearchAndDevelopmentRevenuesFromCollaborationAgreements
12903000
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
77489000
CY2022Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
102972000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
152105000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
118061000
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
8986000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
152105000
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
103303000
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
102972000
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
0
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
0
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
103303000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
102972000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
143142000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
143119000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
9011000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
8986000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
152153000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
152105000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0
us-gaap Depreciation
Depreciation
3100000
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
35700000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
35500000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0
CY2022Q2 mtem Accrued General And Administrative Current
AccruedGeneralAndAdministrativeCurrent
1008000
CY2021Q4 mtem Accrued General And Administrative Current
AccruedGeneralAndAdministrativeCurrent
794000
CY2022Q2 mtem Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
1153000
CY2021Q4 mtem Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
1134000
CY2022Q2 mtem Accrued Non Clinical Research And Manufacturing Operations Current
AccruedNonClinicalResearchAndManufacturingOperationsCurrent
3653000
CY2021Q4 mtem Accrued Non Clinical Research And Manufacturing Operations Current
AccruedNonClinicalResearchAndManufacturingOperationsCurrent
2153000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3408000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5388000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
69000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
46000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9291000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9515000
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
35487000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
33162000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
17574000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13853000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17913000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19309000
CY2022Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
601000
us-gaap Operating Lease Cost
OperatingLeaseCost
1201000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
91000
us-gaap Variable Lease Cost
VariableLeaseCost
211000
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
692000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1412000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7794000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2459000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8444000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
10903000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y1M6D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y7M24D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0701
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0702
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1648000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2689000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2218000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2147000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1559000
CY2022Q2 mtem Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
2686000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
12947000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2044000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
10903000
us-gaap Operating Lease Payments
OperatingLeasePayments
1668000
CY2022Q2 mtem Upfront Fees Unamortized Balance Included In Prepaid Asset
UpfrontFeesUnamortizedBalanceIncludedInPrepaidAsset
100000
CY2022Q2 us-gaap Contractual Obligation
ContractualObligation
38000000.0
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2982000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4513000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6664000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8579000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
23500000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M1D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6697927
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.13
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
13790000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2683818
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.84
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
320716
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.05
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1206556
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
11.46
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7854473
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.21
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
950000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2311953
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.60
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
34509
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.71
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1717209
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
9.74
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8414708
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.25
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
8414708
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
8.25
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4469864
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.95
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1000000.0
mtem Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options1
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions1
0

Files In Submission

Name View Source Status
0001564590-22-029202-index-headers.html Edgar Link pending
0001564590-22-029202-index.html Edgar Link pending
0001564590-22-029202.txt Edgar Link pending
0001564590-22-029202-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gyrc1mz1tndw000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
mtem-10q_20220630.htm Edgar Link pending
mtem-20220630.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mtem-10q_20220630_htm.xml Edgar Link completed
mtem-ex311_8.htm Edgar Link pending
mtem-ex312_6.htm Edgar Link pending
mtem-ex321_9.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
mtem-20220630_lab.xml Edgar Link unprocessable
mtem-20220630_pre.xml Edgar Link unprocessable
mtem-20220630_def.xml Edgar Link unprocessable
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
mtem-20220630_cal.xml Edgar Link unprocessable